Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $9.00, but opened at $9.44. Grifols shares last traded at $9.62, with a volume of 483,885 shares changing hands.
Analysts Set New Price Targets
GRFS has been the subject of several analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a research note on Monday.
Check Out Our Latest Analysis on GRFS
Grifols Price Performance
The company's 50 day moving average price is $8.37 and its 200-day moving average price is $7.73. The stock has a market cap of $6.70 billion, a P/E ratio of 8.33, a P/E/G ratio of 0.32 and a beta of 0.55. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.
Institutional Investors Weigh In On Grifols
Large investors have recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of Grifols during the first quarter valued at about $28,000. Tower Research Capital LLC TRC lifted its position in shares of Grifols by 354.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Grifols during the fourth quarter valued at about $75,000. Envestnet Portfolio Solutions Inc. bought a new position in shares of Grifols during the fourth quarter valued at about $77,000. Finally, Ballentine Partners LLC bought a new position in shares of Grifols during the first quarter valued at about $77,000.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Articles
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.